Fibrotech

The Age Melbourne Magazine – Top 100 – 12th December 2008

admin — Thu, 16 Dec 2010 00:16:48 +0000

The Age compiled a special edition of the Melbourne Magazine to honour the contributions and acheivements of Melbournians across 14 specialty fields. Amongst the “Top 100″ achievers in the field of Science and Health, was Fibrotech’s Director and CEO Associate Professor Darren Kelly. Kelly was commended on his leadership and involvement in the development of FT011. His team were acknowledged for their potential in developing “the worlds first anti-fibrotic drug”.

Media Release – From the Premier of Victoria – 28th October 2008

admin — Mon, 13 Dec 2010 06:56:41 +0000

At Ausbiotech, 28th October 2008, Premier John Brumby announced the $3 million investment funded by the Melbourne Reserch Commercial Fund (MRCF), Brandon Capital and Uniseed to bring FT011 to commercial reality and to ensure this Melbourne drug discovery becomes a workdwide success. Brumby emphasised his Governments support through its Vicstart initiative, working closely with Fibrotech’s commercial and strategic developers, Melbourne Ventures, the University of Melbourne’s commercialisation company.

The Age – 18th August 2008

admin — Fri, 10 Dec 2010 03:13:30 +0000

“Medical Breakthrough – Scientists hail new drug’s potential”

Reported by Jill Sparks

On 18th August 2008, The Age released a publication reporting on the success of Fibrotech’s scientists and their development of the drug, FT011, that may prevent the progression of fibrosis of the heart, kidney’s, lung and liver, which has been reported to be responsible for up to 45% of all deaths in the Western world. The article highlights the international enthusiasm for the development of FT011, including the award of a US Government grant pledging $3 milllion to accelerate Fibotech’s non clinical development